Compare BZAI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BZAI | TARA |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | 254 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.9M | 268.5M |
| IPO Year | N/A | 2014 |
| Metric | BZAI | TARA |
|---|---|---|
| Price | $1.76 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.50 | ★ $21.67 |
| AVG Volume (30 Days) | ★ 7.3M | 586.9K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $239.02 | N/A |
| Revenue Next Year | $46.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $2.77 |
| 52 Week High | $6.76 | $7.82 |
| Indicator | BZAI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 45.35 |
| Support Level | $1.03 | $4.92 |
| Resistance Level | $2.40 | $5.39 |
| Average True Range (ATR) | 0.29 | 0.29 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 47.49 | 47.83 |
Blaize Holdings Inc provides transformative artificial intelligence (AI)-enabled edge computing solutions comprised of both its proprietary hardware and software, and third-party hardware solutions. Its portfolio includes programmable AI processors in various form factors, which can be deployed across sectors such as smart cities, defense, retail, and enterprise markets. The company operates as a single operating and reportable segment. The majority of the company's revenue is derived from Hardware revenue, which includes the sale of its semiconductor products and/or third-party hardware products that support semiconductor products through various supply agreements. Geographically, it generates the maximum revenue from China.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).